Depth and Duration of Response Are Associated With Survival in Patients With Unresectable Hepatocell...
Depth and Duration of Response Are Associated With Survival in Patients With Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150
About this item
Full title
Author / Creator
Journal title
Language
English
Formats
More information
Scope and Contents
Contents
Introduction IMbrave150 established first-line atezolizumab plus bevacizumab as a global standard of care for unresectable hepatocellular carcinoma (HCC). We report exploratory analyses of associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR). Methods IMbrave150 was a phase III randomized study of atez...
Alternative Titles
Full title
Depth and Duration of Response Are Associated With Survival in Patients With Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_crossref_primary_10_1159_000544981
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_crossref_primary_10_1159_000544981
Other Identifiers
ISSN
2235-1795
E-ISSN
1664-5553
DOI
10.1159/000544981
